Chronic Myelogenous Leukaemia

Lee, Stephanie J.

doi:10.1111/j.1365-2141.2000.02216.x

Cited by 25 publications

(9 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Imatinib is the first of a new breed of molecular targeted cancer therapies; it inhibits the abl tyrosine kinase 3 and has become the first-line therapy for CML. With imatinib, nearly all patients achieve hematologic remission 2 and 75% achieve cytogenetic remission. 4 Nonetheless, patients relapse on imatinib discontinuation 4 and may develop resistance.…”

Section: Introductionmentioning

confidence: 99%

Development and dynamics of robust T-cell responses to CML under imatinib treatment

Chen

Maecker

Lee

2008

Blood

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Development and dynamics of robust T-cell responses to CML under imatinib treatment

Chen

Maecker

Lee

2008

Blood

View full text Add to dashboard Cite

“…По данным онкологического регистра США SEER CSR (Surveillance, Epidemiology and Results Cancer Statistic Review), заболеваемость ХМЛ за период с 1996 г. по 2005 г. у пациентов старше 65 лет была в несколько раз выше и достигала 7,9 случая на 100 000 населения против 0,8 случая в возрасте до 65 лет [37].…”

Section: Discussionunclassified

Clinical and Hematological Characteristics of Patients with Chronic Myeloid Leukemia under Present-Day Conditions: Results of the Russian Part of International Multi-Center Prospective EUTOS Population-Based CML Study

Lazareva

Туркина

Chelysheva

et al. 2017

Клиническая онкогематология

View full text Add to dashboard Cite

Background. Much attention has been paid to molecule-genetic diagnostics of chronic myeloid leukemia (CML) and its treatment using new highly effective methods of therapy. The baseline characteristics of patients at primary CML diagnosis are hardly discussed in literature. Aim. To provide clinical, hematological, molecular genetic and demographic characteristics of patients obtained at primary diagnosis of CML. Patients & Methods. Characteristics of CML patients are based on data gathered by the Russian Investigational Group for CML within the international project European Treatment and Outcome Study of CML in Europe (EUTOS, the European Treatment and Outcomes Study). The study included 197 patients with newly diagnosed CML in 6 regions of the Russian Federation (Mordovia, Kirov, Perm (2 sites), Bryansk, Irkutsk, and Chita) over the period from 2009 till 2012. Results. The study demonstrated that 94 % of CML cases were diagnosed in the chronic phase (CP) and 6 % of cases in the acceleration phase (AP) and the blast crisis phase (BC). In 40 % of patients there were no clinical symptoms, and CML was suspected only due to changes in the CBC test. Fatigue was the main subjective complaint presented by 77 % of patients in the CP and 100 % of patients with the AP and BC. Peripheral blood leukocytosis, left shift to immature myeloid cells and increased granulocytic lineage in bone marrow were typical for the patients. In all patients, the CML diagnosis was confirmed by cytogenetic or molecular tests. The social and demographic characteristics of CML patients and comorbidities at diagnosis were analyzed. Conclusion. Based on the results of the study, a modern «portrait of a CML patient» was obtained. The study demonstrated that cytogenetic and molecular methods allow to diagnose CML in most patients at early stages of the disease in the absence of clinical signs of progression. The data on comorbidities require a special attention while choosing a therapy considering its duration. Demographic and social characteristics of CML patients demonstrate that they are socially active, particularly interested in retaining the working capacity and quality of life.

show abstract

“…Imatinib works by blocking the active site of the abl tyrosine kinase enzyme to inhibit uncontrolled division [3]. Under imatinib treatment, nearly all patients achieve hematologic remission [20] and 75% achieve cytogenetic remission [12]. However, imatinib does not completely eliminate leukemia cells and patients still have detectable disease at low levels [33].…”

Section: Biological Backgroundmentioning

confidence: 99%

New Computational Tools for Modeling Chronic Myelogenous Leukemia

Peet

Kim

Niculescu

et al. 2009

Math. Model. Nat. Phenom.

View full text Add to dashboard Cite

Abstract. In this paper, we consider a system of nonlinear delay-differential equations (DDEs) which models the dynamics of the interaction between chronic myelogenous leukemia (CML), imatinib, and the anti-leukemia immune response. Because of the chaotic nature of the dynamics and the sparse nature of experimental data, we look for ways to use computation to analyze the model without employing direct numerical simulation. In particular, we develop several tools using Lyapunov-Krasovskii analysis that allow us to test the robustness of the model with respect to uncertainty in patient parameters. The methods developed in this paper are applied to understanding which model parameters primarily affect the dynamics of the anti-leukemia immune response during imatinib treatment. The goal of this research is to aid the development of more efficient modeling approaches and more effective treatment strategies in cancer therapy.

show abstract

Chronic Myelogenous Leukaemia

Cited by 25 publications

References 133 publications

Development and dynamics of robust T-cell responses to CML under imatinib treatment

Development and dynamics of robust T-cell responses to CML under imatinib treatment

Clinical and Hematological Characteristics of Patients with Chronic Myeloid Leukemia under Present-Day Conditions: Results of the Russian Part of International Multi-Center Prospective EUTOS Population-Based CML Study

New Computational Tools for Modeling Chronic Myelogenous Leukemia

Contact Info

Product

Resources

About